MPharma scales industry across Nigeria
A clear-eyed look at whether $a payroll tool can $reach profitability.
MPharma scales industry across Nigeria
- The real cost behind the Series A.
- Why it matters now for founders — and who it affects first.
- What to watch next as the story develops.
A clear-eyed look at whether $a payroll tool can $reach profitability.
- The real cost behind the Series A.
- Why it matters now for founders — and who it affects first.
- What to watch next as the story develops.
For anyone building in trade & industry, the useful question is where this changes your costs, distribution or competition — and how soon you act on it.
AI-generated summary. It can miss nuance — read the full story above for the complete picture.
Another week, another move from mPharma — but this one changes how operators should think about pricing.
The team's bet is simple: reach profitability without burning the runway that TLcom Capital just extended.
Why it matters
In this economy, unit economics are the strategy.
Strip away the hype and you're left with a practical question about pricing that every operator faces.
Competitors won't sit still. Expect incumbents to respond within the quarter.
What to watch next
- Whether mPharma can hold margins while it chases profitability.
- Whether the Series A buys enough runway to reach the next milestone.
- How Nigeria's regulators respond over the next two quarters.
Founders watching from Johannesburg should take notes: this is how you reach profitability.
